✨ Free AI Report
Zymergen Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Zymergen Inc.
Company Research

Zymergen Inc.: Business Overview, Financials & Competitive Analysis

Zymergen Inc. scores 3/10 on the AskCyborg Cyborg Score (Challenged). A once-promising synthetic biology platform undermined by execution failures and product-market fit challenges; recovery unlikely without significant operational turnaround. Zymergen faces significant structural challenges including a failed flagship product launch (Hyaline), persistent losses despite $883M in historical funding, and major restructuring. Big banks settled a Zymergen IPO investor suit for.

What is Zymergen Inc.'s industry? Zymergen Inc. (zymergen.com) operates in Biotechnology. AskCyborg classifies Zymergen Inc. under Biotechnology in its company registry.

Zymergen is a biotechnology company that specializes in designing and producing molecules, microbes, and materials for diverse end markets through the use of genomics and machine learning. The company has experienced ...

3/ 10Challenged

Cyborg Score thesis

A once-promising synthetic biology platform undermined by execution failures and product-market fit challenges; recovery unlikely...

Read the full analyst-debate transcript →
Industry Biotechnology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Zymergen Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Zymergen Inc.

AskCyborg analysts argue the bull and bear cases for Zymergen Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Zymergen Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Zymergen Inc. Overview

Pro stress-test →

Zymergen is a biotechnology company that specializes in designing and producing molecules, microbes, and materials for diverse end markets through the use of genomics and machine learning. The company has experienced significant challenges post-IPO and now trades as a public company with a market cap of approximately $254M.

Strategic Profile

Pro stress-test →

Ginkgo Bioworks agreed to acquire Zymergen for $300 million in July 2022, though the company remains publicly traded. After going public in April 2021, the company faced manufacturing difficulties and revealed in August 2021 that its flagship Hyaline product was unsuccessful, causing stock prices to plunge. The company has restructured around three business pillars: Advanced Materials, Drug Discovery, and Automation.

Competitive Landscape

Pro stress-test →

Zymergen's competitors include Standard BioTools, BioTork, Ingenza, Arzeda, and Twist Bioscience. The company operates in the synthetic biology and gene-edited materials space, competing with both established biotech firms and younger synthetic biology platforms.

Industry Context

Zymergen Inc. operates in Biotechnology.

Key facts

Founded: 2013 · Headquarters: Emeryville, US · Employees: 49 · Market cap: $254M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Zymergen Inc..

  • As of January 31, 2026, Zymergen has only 49 employees, reflecting substantial downsizing since its IPO peak
  • The company has raised a total of $883M across 5 funding rounds, but failed to translate significant capital into sustained revenue
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026Big banks settled Zymergen IPO investor securities class action for $125 million
  • January 2026Employee count declined to 49, indicating ongoing restructuring
  • +1 moreTrack every material event for Zymergen Inc. as it happens. Explore monitoring →
Get alerted when Zymergen Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Ginkgo BioworksSynthetic biology platform for cell engineering→Twist BioscienceDNA synthesis and gene editing technology→Standard BioToolsBiotech tools and platforms for research→

Compare Zymergen Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Zymergen Inc. operates in Biotechnology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biotechnology by Cyborg Score

Browse Biotechnology research →
NEW · MCP server

Ask your AI assistant about Zymergen Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Zymergen Inc. and its top competitor on Cyborg Score”
“What did Zymergen Inc. do this quarter?”
“Is Zymergen Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Zymergen Inc. do?+
Zymergen is a biotechnology company that specializes in designing and producing molecules, microbes, and materials for diverse end markets through the use of genomics and machine learning. The company has experienced ...
What is Zymergen Inc.'s Cyborg Score?+
Zymergen Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Zymergen Inc.'s main competitors?+
Named competitors include Ginkgo Bioworks, Twist Bioscience, Standard BioTools. The full competitive landscape is in the AskCyborg report.
How can I get the full Zymergen Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Zymergen Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Zymergen Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Abivax SA8Bavarian Nordic A/S8Beam Therapeutics Inc.8CG Oncology, Inc.8Cogent Biosciences, Inc.8COMPASS Pathways plc8CSL Limited8Eckert & Ziegler SE8Krystal Biotech, Inc.8Legend BiotechTop companies in Biotechnology by Cyborg Score